Fernandes Carlos, Allocca Mariangela, Danese Silvio, Fiorino Gionata
Department of Gastroenterology, Centro Hospitalar Vila Nova Gaia, Porto, Portugal.
Immunotherapy. 2015;7(2):175-90. doi: 10.2217/imt.14.105.
Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in inflammatory bowel disease management. Nevertheless, further knowledge and therapeutic indications regarding these drugs are still evolving. Anti-TNF therapy may be essential to achieve recently proposed end points, namely mucosal healing, prevention of bowel damage and prevention of patient's disability. Anti-TNF drugs are also suggested to be more effective in early disease, particularly in early Crohn's disease. Moreover, its efficacy for prevention of postoperative recurrence in Crohn's disease is still debated. Costs and adverse effects, the relevance of drug monitoring and the possibility of anti-TNF therapy withdrawal in selected patients are still debated issues. This review aimed to describe and discuss the most relevant data about the progress with anti-TNF therapy for the management of inflammatory bowel disease.
抗肿瘤坏死因子（TNF）疗法是炎症性肠病治疗中一种有效且日益常用的选择。然而，关于这些药物的更多知识和治疗适应证仍在不断发展。抗TNF疗法对于实现近期提出的终点，即黏膜愈合、预防肠道损伤和预防患者残疾可能至关重要。抗TNF药物在疾病早期，尤其是早期克罗恩病中也被认为更有效。此外，其在预防克罗恩病术后复发方面的疗效仍存在争议。成本和不良反应、药物监测的相关性以及在特定患者中停用抗TNF疗法的可能性仍是有争议的问题。本综述旨在描述和讨论抗TNF疗法在炎症性肠病治疗进展方面的最相关数据。
